# US Geographic Atrophy GA Market > US Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) and By Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.43% - **2024:** $ 5,000 Million - **2025:** $ 5,371.5 Million - **2035:** $ 11,000 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Apellis Pharmaceuticals (US), Alcon (CH), Santen Pharmaceutical (JP), Genentech (CH) **Report ID:** MRFR/HC/14260-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-geographic-atrophy-ga-market-15787 --- ## Market Summary ## **US Geographic Atrophy GA Market Overview** As per MRFR analysis, the US Geographic Atrophy GA Market Size was estimated at 5.29 (USD Billion) in 2023. The US Geographic Atrophy GA Market Industry is expected to grow from 5.75(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 7.314% during the forecast period (2025 - 2035). ### **Key US Geographic Atrophy GA Market Trends Highlighted** The US Geographic Atrophy (GA) market is currently experiencing significant transformation driven by advancements in treatment options and increasing awareness of the disease. One of the key market drivers is the rising prevalence of age-related macular degeneration (AMD), particularly among the aging population. The Centers for Disease Control and Prevention (CDC) notes that the incidence of AMD is projected to rise sharply as the baby boomer generation ages, leading to a greater need for effective management strategies for GA. There are notable opportunities to be explored within this market, particularly in the development of innovative therapies and technologies.Gene therapy and retinal implants are gaining traction as potential treatments that may offer hope to patients suffering from GA. As research continues, pharmaceutical and biotechnological companies are focusing on clinical trials aimed at demonstrating the efficacy of new treatment modalities, thus expanding the therapeutic landscape for geographic atrophy. In recent times, there is a growing emphasis on early diagnosis and preventive care for GA. The integration of advanced diagnostic technologies such as optical coherence tomography (OCT) has improved detection rates, enabling earlier intervention. Moreover, educational initiatives aimed at both healthcare professionals and patients are helping to enhance awareness regarding the symptoms and risk factors associated with GA. This increased understanding is crucial as it encourages timely medical consultations, potentially leading to better outcomes for patients. Overall, the US Geographic Atrophy market is characterized by a convergence of technological advancements, demographic changes, and an enhanced focus on early detection, marking a dynamic shift in how this eye condition is managed and treated in the coming years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Geographic Atrophy GA Market Drivers** #### **Increasing Aging Population** The United States is experiencing a significant demographic shift, with a growing percentage of its population entering the elderly age bracket. This demographic trend is crucial for the US Geographic Atrophy GA Market Industry because age is a major risk factor for geographic atrophy, a progressive condition leading to severe vision loss. According to the U.S. Census Bureau, by 2030, approximately 20% of the U.S. population will be aged 65 or older. This increase in the aging population directly correlates with higher incidences of age-related macular degeneration, including geographic atrophy. The American Academy of Ophthalmology has projected that the prevalence of age-related macular degeneration in adults over 50 years will increase by nearly 50% between 2015 and 2050, further driving the need for effective treatment and management options in the US Geographic Atrophy GA Market Industry. #### **Advancements in Research and Development** There has been notable progress in the Research and Development (R&D) sector concerning treatments and therapies for geographic atrophy in the United States. Major pharmaceutical companies, such as Genentech and Regeneron Pharmaceuticals, have been actively investing in novel treatment options, including gene therapy and other innovative therapies aimed at treating retinal diseases. The National Institutes of Health (NIH) reported that funding allocated for eye disease research has seen a steady increase, amounting to over USD 700 million in 2022 alone.These investments not only advance the understanding of geographic atrophy but also facilitate the development of new products, enhancing the overall US Geographic Atrophy GA Market Industry landscape. #### **Growing Awareness and Early Diagnosis Initiatives** The rise in public awareness and the implementation of early diagnosis initiatives significantly support the US Geographic Atrophy GA Market Industry. Health organizations and non-profits, such as the Retina Society and the Foundation Fighting Blindness, have increased efforts in educating patients and healthcare professionals about the risks and symptoms of geographic atrophy. Increasing awareness has been associated with improved screening rates, with the American Optometric Association estimating that over 40% of individuals with vision impairment are unaware of their condition.When conditions are caught earlier, the management options and outcomes often improve, leading to a growing market for geographic atrophy treatments in the US. ### **US Geographic Atrophy GA Market Segment Insights** #### **Geographic Atrophy GA Market Age Group Insights** The Age Group segment of the US Geographic Atrophy GA Market is characterized by a significant focus on older populations, particularly individuals Above 60 Years and Above 75 Years. This demographic is critical due to the increasing prevalence of Geographic Atrophy, which is more commonly diagnosed in older adults. With the aging population in the United States, driven by advancements in healthcare and higher life expectancy, a substantial proportion of the market is driven by conditions affecting older adults. As a result, individuals above the age of 60 represent a majority holding within this market, showcasing the high risk and necessity for advanced treatment options.The segment of individuals Above 75 Years is particularly significant, experiencing a higher incidence rate of Geographic Atrophy due to cumulative health factors associated with aging. These segments not only dominate in terms of patient numbers but also highlight the evolving therapeutic landscape as industry players seek to develop more effective interventions tailored for these vulnerable age groups. The overall healthcare market continues to respond to the needs of this aging population, presenting opportunities for innovation in the treatment approaches addressing both prevention and management of Geographic Atrophy.Tailored healthcare solutions, educational initiatives, and enhanced screening strategies will be essential in catering to the specific needs of these age groups, thereby impacting the overall market dynamics powerfully. The growing awareness of eye health among older adults, supported by nutritional and lifestyle changes, also contributes to shifts in treatment demand, indicating an evolving market landscape shaped significantly by the Age Group segment. As the US population ages, the need for comprehensive management and preventive care in the Geographic Atrophy GA Market will undoubtedly shape both industry practices and patient outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **Geographic Atrophy GA Market Diagnosis Insights** The Diagnosis segment of the US Geographic Atrophy GA Market is a critical area of focus, as effective diagnosis is vital for managing and treating this progressive eye disease. Employing advanced imaging technologies, such as Fundus Autofluorescence, allows for the detection of retinal changes and helps to monitor disease progression more effectively. Optical Coherence Tomography Angiography contributes to a comprehensive assessment of retinal vasculature, enabling physicians to identify abnormalities that may indicate the onset of [Geographic Atrophy](../../../reports/geographic-atrophy-ga-market-10781). Meanwhile, Multifocal Electroretinography provides vital information on retinal function, offering insights into functional impairments caused by the disease. Given that the prevalence of Geographic Atrophy is rising in the aging population, the demand for accurate diagnostic tools is increasing, creating opportunities for innovation and growth within this segment. These technologies not only enhance diagnostic accuracy but also play a significant role in shaping future treatment strategies, thereby influencing the overall landscape of the US Geographic Atrophy GA Market.As investment in Research and Development continues, advancements in these diagnostic methods are likely to foster better patient outcomes and optimize resource allocation in clinical settings. #### **Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights** The Therapeutic Agents Clinical Phase segment within the US Geographic Atrophy GA Market is crucial for addressing critical needs in treating this condition. As the market evolves, the Late-Stage category signifies the most promising potential therapies, showcasing innovations that could significantly improve patient outcomes. The Phase II and Phase I areas are vital for assessing efficacy and safety, often representing the transitional phase where insights gleaned from earlier stages influence final product developments. Pre-Clinical Stage research serves as the foundation for future therapeutic candidates, focusing on understanding biological mechanisms and identifying unique targets for intervention.Discovery Candidates highlight the potential for groundbreaking treatments, underscoring the importance of ongoing Research and Development activities in the market. Collaborative efforts among academia, industry, and regulatory bodies are essential to streamline the development process, ultimately leading to increased US Geographic Atrophy GA Market revenue and improving patient care landscapes. With robust investments and advancements, these segments provide vast opportunities within the market as they contribute to innovative therapeutic solutions addressing unmet medical needs. ### **US Geographic Atrophy GA Market Key Players and Competitive Insights** The US Geographic Atrophy GA market is witnessing significant evolution, propelled by advancements in research and increasing investments in the development of innovative therapies aimed at slowing disease progression. Geographic Atrophy, a progressive condition linked with age-related macular degeneration, presents both challenges and opportunities for pharmaceutical companies focusing on ophthalmology. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all vying to capture market share through novel treatment options and strategic partnerships. This dynamic environment is further influenced by regulatory pathways, reimbursement policies, and the growing emphasis on patient-centric care, driving companies to enhance their product offerings and operational efficiency to address unmet medical needs. Genentech has established a formidable presence in the US Geographic Atrophy GA market, focusing on research-driven initiatives aimed at developing treatments that address the complexity of this condition. The company's strength lies in its robust pipeline and commitment to innovative therapies, leveraging its extensive experience in the ophthalmology sector. Genentech’s strategic collaborations and partnerships contribute to its capability in exploring cutting-edge solutions for geographic atrophy, emphasizing the importance of clinical trials that incorporate patient feedback. The company’s established brand reputation enhances its competitive edge, enabling it to effectively engage with healthcare providers and patients while navigating the regulatory landscape to expedite the availability of its treatment options. Novartis is another key player in the US Geographic Atrophy GA market, known for its diverse portfolio that includes therapies specifically targeting ocular conditions. With a well-established presence in the pharmaceutical landscape, Novartis leverages its research and development expertise to enhance treatment protocols and improve patient outcomes in geographic atrophy management. The company’s strengths are further bolstered by its strategic mergers and acquisitions that expand its capabilities and market reach. Key products in Novartis’ pipeline demonstrate a strong focus on innovative approaches to addressing geographic atrophy, and the company's commitment to patient-centric solutions enables it to maintain competitive advantage. Through its extensive distribution network and engagement with stakeholders, Novartis effectively positions itself as a leader in delivering effective therapies for geographic atrophy in the US market. ### **Key Companies in the US Geographic Atrophy GA Market Include** ### **US Geographic Atrophy GA Market Industry Developments** The US Geographic Atrophy (GA) Market has seen significant developments recently. In April 2023, Iveric Bio announced positive results from its Phase 3 trials for Zimura, a novel treatment targeting GA, which has since garnered attention for its therapeutic potential. In May 2023, Apellis Pharmaceuticals also reported promising data for Syfovre, its innovative therapy for GA, indicating substantial strides in the treatment landscape. Meanwhile, Genentech is actively advancing its pipeline with new compounds, focusing on innovative approaches to address retinal diseases, which has influenced market dynamics. In terms of acquisitions, in August 2023, Novartis completed its acquisition of AveXis, enhancing its capabilities in gene therapies, which may have implications for future GA treatment modalities. The market valuation for companies within the GA sector, including EyePoint Pharmaceuticals and Regeneron Pharmaceuticals, has experienced overall growth driven by advancements in Research and Development and positive clinical trial outcomes. Regulatory changes focusing on accelerated approval pathways have also fueled investor interest and market expansion, laying a promising foundation for future innovations in the US Geographic Atrophy Market. ### **US Geographic Atrophy GA Market Segmentation Insights** #### **Geographic Atrophy GA Market Age Group Outlook** #### **Geographic Atrophy GA Market Diagnosis Outlook** #### **Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook** ## Market Drivers ### Advancements in Diagnostic Technologies Technological advancements in diagnostic tools are transforming the landscape of the geographic atrophy-ga market. Enhanced imaging techniques, such as optical coherence tomography (OCT) and fundus autofluorescence, allow for earlier and more accurate detection of geographic atrophy. These innovations facilitate timely intervention, which is crucial for managing the progression of the disease. As diagnostic capabilities improve, healthcare providers are better equipped to identify at-risk patients, leading to increased treatment initiation rates. The market for diagnostic devices is expected to grow, with estimates indicating a potential increase of 15% annually. This growth in diagnostic technology not only enhances patient outcomes but also stimulates demand for therapeutic solutions within the geographic atrophy-ga market. ### Growing Investment in Ophthalmic Research The geographic atrophy-ga market is experiencing a surge in investment directed towards ophthalmic research. Public and private funding initiatives are increasingly focusing on the development of novel therapies and treatment modalities for retinal diseases. In recent years, funding for ophthalmic research has seen an uptick, with estimates suggesting an increase of over 20% in research grants allocated to retinal diseases. This influx of capital is likely to accelerate the pace of clinical trials and the introduction of innovative therapies. As researchers explore new avenues for treatment, the geographic atrophy-ga market stands to benefit from a broader array of therapeutic options, ultimately enhancing patient care and outcomes. ### Regulatory Support for Innovative Treatments Regulatory bodies are increasingly supportive of innovative treatments for geographic atrophy, which is likely to drive market growth. Initiatives such as expedited review processes and orphan drug designations are designed to encourage the development of therapies for rare diseases, including geographic atrophy. The U.S. Food and Drug Administration (FDA) has implemented programs that facilitate faster access to new treatments, which may lead to a quicker introduction of effective therapies into the market. This regulatory environment fosters innovation and investment in the geographic atrophy-ga market, as companies are incentivized to develop and bring new solutions to patients in need. ### Increased Awareness and Education Initiatives Raising awareness about geographic atrophy and its implications is becoming a pivotal driver in the market. Educational campaigns aimed at both healthcare professionals and the general public are essential for improving understanding of the disease. As awareness grows, patients are more likely to seek medical advice and treatment, which could lead to an increase in diagnosed cases. Recent surveys indicate that nearly 60% of individuals over 50 are unaware of geographic atrophy, highlighting a significant opportunity for educational outreach. This increased awareness is expected to translate into higher demand for therapies, thereby positively impacting the geographic atrophy-ga market. ### Rising Prevalence of Age-Related Macular Degeneration The increasing incidence of age-related macular degeneration (AMD) is a critical driver for the geographic atrophy-ga market. As the population ages, particularly among individuals aged 65 and older, the prevalence of AMD is projected to rise significantly. Current estimates suggest that approximately 2.1 million Americans are affected by AMD, with a notable portion developing geographic atrophy. This demographic shift indicates a growing patient population that requires effective treatment options. Consequently, pharmaceutical companies are likely to invest in research and development to address this unmet medical need, thereby propelling the geographic atrophy-ga market forward. The aging population, combined with the increasing awareness of eye health, suggests a robust demand for innovative therapies targeting geographic atrophy. ## Future Outlook The [Geographic Atrophy GA Market](https://www.marketresearchfuture.com/reports/geographic-atrophy-ga-market-10781) is projected to grow at a 7.43% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness. **New opportunities:** - Development of personalized treatment plans leveraging AI technology. - Expansion of telehealth services for remote patient monitoring. - Investment in clinical trials for novel therapeutic agents. By 2035, the market is expected to achieve substantial growth, driven by innovative solutions and increased demand. ## Segment Insights ### By Age Group: Above 60 Years (Largest) vs. Above 75 Years (Fastest-Growing) In the US geographic atrophy-ga market, the age group above 60 years holds the largest market share. This segment captures a significant portion due to the increasing prevalence of geographic atrophy among older populations, driven by age-related health issues. Meanwhile, the above 75 years segment is rapidly gaining traction, showcasing a notable increase in market engagement and awareness of treatment options specific to older adults. The growth for the above 75 years segment is primarily fueled by demographic shifts and heightened focus on age-related diseases. As healthcare providers become more attuned to the needs of older patients, innovations in treatment are becoming accessible, leading to an increase in diagnosis and management. Public health initiatives aimed at educating and engaging older adults further contribute to the expanding footprint of this demographic in the market. Above 60 Years (Dominant) vs. Above 75 Years (Emerging) The age group above 60 years is the dominant segment in the US geographic atrophy-ga market, characterized by a large, well-established patient base and a broad range of available treatment options. This group benefits from significant healthcare infrastructure and support systems designed to cater to their needs. Conversely, the segment above 75 years is emerging, showing rapid growth as healthcare providers recognize the unique challenges faced by this older demographic. With an increasing focus on personalized care for older adults, this segment is positioned to expand significantly, driven by advancements in treatment protocols and greater patient advocacy. The distinct characteristics of these age groups emphasize the importance of tailored approaches in addressing geographic atrophy. ### By Diagnosis: Fundus Autofluorescence (Largest) vs. Optical Coherence Tomography Angiography (Fastest-Growing) In the US geographic atrophy-ga market, the Fundus Autofluorescence (FAF) segment holds a significant share due to its established role in diagnosing and monitoring retinal diseases. This traditional imaging technique has been the go-to method for detecting geographic atrophy and continues to dominate the market. Meanwhile, Optical Coherence Tomography Angiography (OCT-A) is rapidly gaining traction, providing deeper insights into choroidal and retinal blood flow, appealing to healthcare providers seeking comprehensive diagnostic tools. The growth trends in this segment are primarily driven by the increasing prevalence of age-related macular degeneration and advancements in imaging technologies. The demand for non-invasive diagnostics has fueled interest in OCT-A, positioning it as an emerging favorite among clinicians. As awareness of these diagnostic tools expands, both FAF and OCT-A are expected to play pivotal roles in shaping the future landscape of ophthalmic diagnostics in the market. Fundus Autofluorescence (Dominant) vs. Optical Coherence Tomography Angiography (Emerging) Fundus Autofluorescence (FAF) remains the dominant technique in the US geographic atrophy-ga market, renowned for its ability to highlight lipofuscin accumulation in retinal cells, thereby aiding in the diagnosis of various retinal pathologies. Its longstanding presence in clinical practice makes it a reliable choice for practitioners. In contrast, Optical Coherence Tomography Angiography (OCT-A) is an emerging technology that offers unparalleled visualization of the retinal and choroidal vasculature with minimal invasiveness. This innovative imaging method not only enhances diagnostic accuracy but also aids in monitoring disease progression, making it a key player as it gains acceptance among ophthalmologists and is poised for rapid growth in adoption. ### By Therapeutic Agents Clinical Phase: Late-Stage (Largest) vs. Phase II (Fastest-Growing) The US geographic atrophy-ga market is witnessing significant activity across various therapeutic agents in different clinical phases. Among them, the Late-Stage (Phase III) segment commands the largest share, reflecting a mature stage of development where solutions are ready for final efficacy testing. In contrast, the Phase II segment is rapidly gaining momentum, showcasing promising results that could enhance its market position in the upcoming years. Growth trends in this segment are heavily influenced by advancements in clinical research methodologies, an increase in investment towards innovative treatments, and the urgency to address unmet needs of patients. The rising prevalence of geographic atrophy and the potential for long-lasting benefits from new therapeutic agents are vital drivers contributing to the expanding Phase II segment, which is now recognized as the fastest-growing path within the therapeutic landscape. Late-Stage (Dominant) vs. Phase II (Emerging) The Late-Stage (Phase III) segment remains the dominant force in the therapeutic agents landscape, characterized by its robust pipeline of drugs awaiting approval and market launch. This stage typically involves large clinical trials that ascertain the safety and efficacy of treatments, making it a critical juncture that attracts significant investment and regulatory attention. On the other hand, the Phase II segment, while currently smaller in market share, is emerging as a pivotal phase where therapies frequently demonstrate promising efficacy. The focus on innovative treatment mechanisms, adaptive trial designs, and patient-centric approaches are facilitating rapid advancements in the Phase II stage, signaling a dynamic environment poised for future growth against the backdrop of an increasing demand for effective geographic atrophy solutions. ## Competitive Benchmarking The geographic atrophy-ga market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative treatment options. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Apellis Pharmaceuticals (US) are actively shaping the market through strategic initiatives. Novartis (CH) focuses on advancing its research and development capabilities, particularly in gene therapy, which may enhance its competitive edge. Regeneron Pharmaceuticals (US) appears to be leveraging its strong pipeline of biologics, aiming to address unmet needs in the treatment of geographic atrophy. Meanwhile, Apellis Pharmaceuticals (US) is concentrating on expanding its commercial footprint, particularly in the U.S. market, which could significantly influence market dynamics.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. However, the collective influence of these key players is substantial, as they drive innovation and set industry standards, thereby shaping the competitive environment. In October Novartis (CH) announced a strategic partnership with a leading biotechnology firm to co-develop a novel treatment for geographic atrophy. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, indicating Novartis's commitment to innovation and collaboration in addressing this challenging condition. In September Regeneron Pharmaceuticals (US) reported positive results from a pivotal clinical trial for its new biologic therapy targeting geographic atrophy. The promising data not only strengthens Regeneron's position in the market but also highlights the potential for biologics to transform treatment paradigms, suggesting a shift towards more targeted therapies in the future. In August Apellis Pharmaceuticals (US) launched a comprehensive awareness campaign aimed at educating healthcare providers and patients about geographic atrophy. This initiative underscores Apellis's focus on market penetration and patient engagement, which may enhance its competitive positioning as it seeks to establish itself as a leader in this therapeutic area. As of November current trends in the geographic atrophy-ga market include a pronounced emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, it appears that competitive differentiation will evolve, with a notable shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability, which may redefine success in this market. ## Recent News & Developments The US Geographic Atrophy (GA) Market has seen significant developments recently. In April 2023, Iveric Bio announced positive results from its Phase 3 trials for Zimura, a novel treatment targeting GA, which has since garnered attention for its therapeutic potential. In May 2023, Apellis Pharmaceuticals also reported promising data for Syfovre, its innovative therapy for GA, indicating substantial strides in the treatment landscape. Meanwhile, Genentech is actively advancing its pipeline with new compounds, focusing on innovative approaches to address retinal diseases, which has influenced market dynamics. In terms of acquisitions, in August 2023, Novartis completed its acquisition of AveXis, enhancing its capabilities in gene therapies, which may have implications for future GA treatment modalities. The market valuation for companies within the GA sector, including EyePoint Pharmaceuticals and Regeneron Pharmaceuticals, has experienced overall growth driven by advancements in Research and Development and positive clinical trial outcomes. Regulatory changes focusing on accelerated approval pathways have also fueled investor interest and market expansion, laying a promising foundation for future innovations in the US Geographic Atrophy Market. ## Report Scope | MARKET SIZE 2024 | 5000.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 5371.5(USD Million) | | MARKET SIZE 2035 | 11000.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.43% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Apellis Pharmaceuticals (US), Alcon (CH), Santen Pharmaceutical (JP), Genentech (CH) | | Segments Covered | Age Group, Diagnosis, Therapeutic Agents Clinical Phase | | Key Market Opportunities | Advancements in gene therapy and novel treatment modalities present growth potential in the geographic atrophy-ga market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the geographic atrophy market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation for the US geographic atrophy-ga market in 2024?** A: The overall market valuation for the US geographic atrophy-ga market was $5000.0 Million in 2024. **Q: What is the projected market valuation for the US geographic atrophy-ga market by 2035?** A: The projected market valuation for the US geographic atrophy-ga market is $11000.0 Million by 2035. **Q: What is the expected CAGR for the US geographic atrophy-ga market during the forecast period 2025 - 2035?** A: The expected CAGR for the US geographic atrophy-ga market during the forecast period 2025 - 2035 is 7.43%. **Q: Which age group represents the largest market segment for geographic atrophy in the US?** A: The age group 'Above 60 Years' represents the largest market segment, with valuations ranging from $3000.0 Million to $6600.0 Million. **Q: What diagnostic methods are utilized in the US geographic atrophy-ga market?** A: Key diagnostic methods include Fundus Autofluorescence (FAF) and Optical Coherence Tomography Angiography (OCT-A), with valuations of $1500.0 Million to $3300.0 Million and $2000.0 Million to $4400.0 Million, respectively. **Q: What are the clinical phases of therapeutic agents in the US geographic atrophy-ga market?** A: The clinical phases include Late-Stage (Phase III) with valuations of $2000.0 Million to $4400.0 Million, and Pre-Clinical Stage & Discovery Candidates valued at $1500.0 Million to $3100.0 Million. **Q: Who are the key players in the US geographic atrophy-ga market?** A: Key players in the market include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Apellis Pharmaceuticals, Alcon, Santen Pharmaceutical, and Genentech. **Q: What is the market valuation range for the age group 'Above 75 Years'?** A: The market valuation range for the age group 'Above 75 Years' is from $2000.0 Million to $4400.0 Million. **Q: How does the market for Optical Coherence Tomography Angiography (OCT-A) compare to other diagnostic methods?** A: The market for Optical Coherence Tomography Angiography (OCT-A) is projected to be higher, with valuations between $2000.0 Million and $4400.0 Million, compared to other methods. **Q: What is the significance of the projected growth in the US geographic atrophy-ga market?** A: The projected growth indicates a robust market expansion, potentially reaching $11000.0 Million by 2035, driven by advancements in treatment and diagnosis. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-geographic-atrophy-ga-market-15787*